KalVista Pharmaceuticals (KALV) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

KalVista Pharmaceuticals Revenue Highlights


00

KalVista Pharmaceuticals Revenue by Period


KalVista Pharmaceuticals Revenue by Year

DateRevenueChange
2024-04-30-100.00%
2023-04-30-100.00%
2022-04-30--100.00%
2021-04-30$12.69M-
2020-04-30$12.69M-21.31%
2019-04-30$16.13M92.13%
2018-04-30$8.39M458.11%
2017-04-30$1.50M-29.49%
2016-04-30$2.13M18.24%
2015-04-30$1.80M334.70%
2013-12-31$415.00K-73.02%
2012-12-31$1.54M-

KalVista Pharmaceuticals generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

KalVista Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-07-31--100.00%
2024-04-30$1.21M100.00%
2024-01-31-100.00%
2023-10-31-100.00%
2023-07-31-100.00%
2023-04-30-100.00%
2023-01-31-100.00%
2022-10-31-100.00%
2022-07-31-100.00%
2022-04-30-100.00%
2022-01-31-100.00%
2021-10-31-100.00%
2021-07-31--100.00%
2021-04-30$12.69M100.00%
2021-01-31-100.00%
2020-10-31-100.00%
2020-07-31--100.00%
2020-04-30$3.82M142.49%
2020-01-31$1.58M-59.77%
2019-10-31$3.92M16.36%
2019-07-31$3.37M15.14%
2019-04-30$2.93M-24.78%
2019-01-31$3.89M-30.44%
2018-10-31$5.59M50.40%
2018-07-31$3.72M-23.18%
2018-04-30$4.84M107.64%
2018-01-31$2.33M106.83%
2017-10-31$1.13M1073.96%
2017-07-31$96.00K-15.79%
2017-04-30$114.00K-54.03%
2017-01-31$248.00K100.00%
2016-09-30--100.00%
2016-06-30$7.00K-
2016-03-31$7.00K-12.50%
2015-12-31$8.00K14.29%
2015-09-30$7.00K-
2015-06-30$7.00K-12.50%
2014-12-31$8.00K-20.00%
2014-09-30$10.00K100.00%
2014-06-30$5.00K-16.67%
2014-03-31$6.00K-98.49%
2013-12-31$398.00K-

KalVista Pharmaceuticals generated - in revenue during Q1 2025, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

KalVista Pharmaceuticals Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
IMCRImmunocore$249.43M$75.40M
MIRMMirum Pharmaceuticals$186.37M$69.22M
MRSNMersana Therapeutics$36.85M$2.29M
CYTKCytokinetics$7.53M$249.00K
KRONKronos Bio$6.29M$2.69M
CRNXCrinetics Pharmaceuticals$4.01M$640.00K
LYRALyra Therapeutics$1.56M$598.00K
KRTXKaruna Therapeutics$654.00K-
VRDNViridian Therapeutics$314.00K$72.00K
CGEMCullinan Oncology--
COGTCogent Biosciences--
GOSSGossamer Bio-$95.84M
DICEDICE Therapeutics--
DYNDyne Therapeutics--
REPLReplimune Group--
KURAKura Oncology--
SNDXSyndax Pharmaceuticals-$3.50M
LRMRLarimar Therapeutics--
NVCTNuvectis Pharma--
KALVKalVista Pharmaceuticals--
EWTXEdgewise Therapeutics--

KALV Revenue FAQ


KalVista Pharmaceuticals's yearly revenue for 2024 was $0, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. KALV's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021.

KalVista Pharmaceuticals's quarterly revenue for Q1 2025 was $0, a -100.00% decrease from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $1.21M, a 100.00% increase from the previous quarter (Q3 2024), and a 0% increase year-over-year (Q4 2023). KALV's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023).

KalVista Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was -100.00%.